Vaccinex, Inc. (VCNX)
OTCMKTS
· Delayed Price · Currency is USD
0.6995
+0.0097 (1.40%)
At close: Dec 4, 2025
Vaccinex Employees
As of December 31, 2024, Vaccinex had 27 total employees, including 23 full-time and 4 part-time employees. The number of employees decreased by 13 or -32.50% compared to the previous year.
Employees
27
Change (1Y)
-13
Growth (1Y)
-32.50%
Revenue / Employee
$24,040
Profits / Employee
-$745,360
Market Cap
1.87M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Elite Pharmaceuticals | 68 |
| Glass House Brands | 374 |
| CytoDyn | 13 |
| American Oncology Network | 1,914 |
| Northwest Biotherapeutics | 25 |
| Silence Therapeutics | 116 |
| Zomedica | 152 |
Vaccinex News
- 6 months ago - Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting - GlobeNewsWire
- 8 months ago - Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) - GlobeNewsWire
- 9 months ago - Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market - GlobeNewsWire
- 10 months ago - ARMISTICE CAPITAL, LLC Reduces Stake in Vaccinex Inc: A Strategic Portfolio Adjustment - GuruFocus
- 1 year ago - Vaccinex Faces Nasdaq Delisting: What's Going On With The Stock? - Benzinga
- 1 year ago - Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 1 year ago - Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC - GlobeNewsWire
- 1 year ago - Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting - GlobeNewsWire